INCYIncyte Corporation
Healthcare · BiotechnologyNasdaqStockMkt cap $25.5B
Disclosed trades
2
0 in 30d · 0 in 90d
Politicians
2
Last trade May 15, 2025
Buys
0
$0 at range midpoints
Sells
2
$16K at range midpoints
Closing price · 365 days
Sep 24, 2025 – Sep 23, 2026
Monthly buys vs sells · 24 months
Counts of disclosed transactions
- Buys
- Sells (incl. partial)
Politicians who traded it
| Politician | Seat | Trades | Buys | Sells | Bought (mid) | Sold (mid) | Last trade | Est. position Estimated |
|---|---|---|---|---|---|---|---|---|
| DDaniel S. Goldman | House · NY-10 | 1 | 0 | 1 | $0 | $8K | Mar 6, 2023 | — |
| RRobert P. Bresnahan, Jr. | House · PA-08 | 1 | 0 | 1 | $0 | $8K | May 15, 2025 | — |
Recent trades
| Politician | Ticker | Asset | Type | Owner | Amount | Traded | Filed | Source |
|---|---|---|---|---|---|---|---|---|
| RRobert P. Bresnahan, Jr. | INCY | Incyte Corporation - Common Stock (INCY) | Sell | Self | $1,001 - $15,000 | May 15, 2025 | May 31, 202516d | Filing |
| DDaniel S. Goldman | INCY | Incyte Corporation (INCY) | Sell | Self | $1,001 - $15,000 | Mar 6, 2023 | Apr 17, 202342d | Filing |
Insider activity Filed
Insiders
28
Services-Commercial Physical & Biological Research
Open-market buys · 90d
0
$0 bought
Open-market sells · 90d
22
$18.2M sold
Net · 90d
-$18.2M
-$58.3M net over 12 months · last Sep 15, 2026
| Date | Insider | Kind | Security | Shares | Price | Value | Post-holdings | D/I | 10b5-1 | Source |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 15, 2026filed Sep 17, 2026 | Pablo J CagnoniPresident, Global Head of R&D | Exercise | Employee Stock Option (right to buy)deriv. | −9,233 | $0.00 | — | 18,466 | D | 10b5-1 | 4 |
| Sep 15, 2026filed Sep 17, 2026 | Pablo J CagnoniPresident, Global Head of R&D | Exercise | Employee Stock Option (right to buy)deriv. | −6,477 | $0.00 | — | 20,356 | D | 10b5-1 | 4 |
| Sep 15, 2026filed Sep 17, 2026 | Pablo J CagnoniPresident, Global Head of R&D | Exercise | Employee Stock Option (right to buy)deriv. | −4,551 | $0.00 | — | 4,551 | D | 10b5-1 | 4 |
| Sep 15, 2026filed Sep 17, 2026 | Pablo J CagnoniPresident, Global Head of R&D | Exercise | Employee Stock Option (right to buy)deriv. | −2,957 | $0.00 | — | 4,225 | D | 10b5-1 | 4 |
| Sep 15, 2026filed Sep 17, 2026 | Pablo J CagnoniPresident, Global Head of R&D | Sale | Common Stock | −13,985 | $120.49 | $1,685,053 | 183,200 | D | 10b5-1 | 4 |
| Sep 15, 2026filed Sep 17, 2026 | Pablo J CagnoniPresident, Global Head of R&D | Sale | Common Stock | −9,233 | $120.50 | $1,112,577 | 197,185 | D | 10b5-1 | 4 |
| Sep 15, 2026filed Sep 17, 2026 | Pablo J CagnoniPresident, Global Head of R&D | Exercise | Common Stock | 9,233 | $71.93 | $664,130 | 206,418 | D | 10b5-1 | 4 |
| Sep 15, 2026filed Sep 17, 2026 | Pablo J CagnoniPresident, Global Head of R&D | Exercise | Common Stock | 6,477 | $64.25 | $416,147 | 197,185 | D | 10b5-1 | 4 |
| Sep 15, 2026filed Sep 17, 2026 | Pablo J CagnoniPresident, Global Head of R&D | Exercise | Common Stock | 4,551 | $61.18 | $278,430 | 190,708 | D | 10b5-1 | 4 |
| Sep 15, 2026filed Sep 17, 2026 | Pablo J CagnoniPresident, Global Head of R&D | Exercise | Common Stock | 2,957 | $61.76 | $182,624 | 186,157 | D | 10b5-1 | 4 |
Shares, prices and post-transaction holdings are exactly as reported on SEC Form 4. Net figures count open-market buys minus open-market sales only (awards, exercises, withholding and gifts are excluded).